Adalimumab in ulcerative colitis–efficacy, safety and optimization in the era of treat-to target

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: Active ulcerative colitis is associated with significant morbidity and impairment to quality of life. Adalimumab is a welcome addition to the therapeutic armamentarium for clinicians treating patients with moderate-severe ulcerative colitis refractory to conventional therapies, an indication with few prior treatment options. It offers the convenience of self-injection and is most appropriate for outpatients with moderate disease activity. Areas covered: This review briefly summarizes data from well-designed clinical trials and observational real-life studies that demonstrate the safety and efficacy of adalimumab in UC. Particular attention is paid to newer studies, including those with objective treatment endpoints and pharmacokinetic outcomes that incorporate a treat to target approach in inflammatory bowel disease. Expert opinion: Adalimumab is effective for the induction and maintenance of remission in patients with moderate-severe ulcerative colitis refractory to conventional therapies. At currently approved doses, it is most suitable for use in outpatients with moderate disease activity; higher doses may be required for patients with more severe disease. The convenience of self-injection will make it popular for remote patients and it may be an appropriate option in patients in whom monotherapy, rather than combination therapy with an immunomodulator, is preferred.

Original languageEnglish
Pages (from-to)613-621
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume17
Issue number5
DOIs
Publication statusPublished - 4 May 2017

Keywords

  • Adalimumab
  • anti-tumor necrosis factor alpha agents
  • biologic therapies
  • inflammatory bowel disease
  • treat to target
  • ulcerative colitis

Cite this

@article{a0b844fb7332484b8e36d8a17a2a1afe,
title = "Adalimumab in ulcerative colitis–efficacy, safety and optimization in the era of treat-to target",
abstract = "Introduction: Active ulcerative colitis is associated with significant morbidity and impairment to quality of life. Adalimumab is a welcome addition to the therapeutic armamentarium for clinicians treating patients with moderate-severe ulcerative colitis refractory to conventional therapies, an indication with few prior treatment options. It offers the convenience of self-injection and is most appropriate for outpatients with moderate disease activity. Areas covered: This review briefly summarizes data from well-designed clinical trials and observational real-life studies that demonstrate the safety and efficacy of adalimumab in UC. Particular attention is paid to newer studies, including those with objective treatment endpoints and pharmacokinetic outcomes that incorporate a treat to target approach in inflammatory bowel disease. Expert opinion: Adalimumab is effective for the induction and maintenance of remission in patients with moderate-severe ulcerative colitis refractory to conventional therapies. At currently approved doses, it is most suitable for use in outpatients with moderate disease activity; higher doses may be required for patients with more severe disease. The convenience of self-injection will make it popular for remote patients and it may be an appropriate option in patients in whom monotherapy, rather than combination therapy with an immunomodulator, is preferred.",
keywords = "Adalimumab, anti-tumor necrosis factor alpha agents, biologic therapies, inflammatory bowel disease, treat to target, ulcerative colitis",
author = "Sparrow, {Miles P.}",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14712598.2017.1309390",
language = "English",
volume = "17",
pages = "613--621",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor & Francis",
number = "5",

}

Adalimumab in ulcerative colitis–efficacy, safety and optimization in the era of treat-to target. / Sparrow, Miles P.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 5, 04.05.2017, p. 613-621.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Adalimumab in ulcerative colitis–efficacy, safety and optimization in the era of treat-to target

AU - Sparrow, Miles P.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Active ulcerative colitis is associated with significant morbidity and impairment to quality of life. Adalimumab is a welcome addition to the therapeutic armamentarium for clinicians treating patients with moderate-severe ulcerative colitis refractory to conventional therapies, an indication with few prior treatment options. It offers the convenience of self-injection and is most appropriate for outpatients with moderate disease activity. Areas covered: This review briefly summarizes data from well-designed clinical trials and observational real-life studies that demonstrate the safety and efficacy of adalimumab in UC. Particular attention is paid to newer studies, including those with objective treatment endpoints and pharmacokinetic outcomes that incorporate a treat to target approach in inflammatory bowel disease. Expert opinion: Adalimumab is effective for the induction and maintenance of remission in patients with moderate-severe ulcerative colitis refractory to conventional therapies. At currently approved doses, it is most suitable for use in outpatients with moderate disease activity; higher doses may be required for patients with more severe disease. The convenience of self-injection will make it popular for remote patients and it may be an appropriate option in patients in whom monotherapy, rather than combination therapy with an immunomodulator, is preferred.

AB - Introduction: Active ulcerative colitis is associated with significant morbidity and impairment to quality of life. Adalimumab is a welcome addition to the therapeutic armamentarium for clinicians treating patients with moderate-severe ulcerative colitis refractory to conventional therapies, an indication with few prior treatment options. It offers the convenience of self-injection and is most appropriate for outpatients with moderate disease activity. Areas covered: This review briefly summarizes data from well-designed clinical trials and observational real-life studies that demonstrate the safety and efficacy of adalimumab in UC. Particular attention is paid to newer studies, including those with objective treatment endpoints and pharmacokinetic outcomes that incorporate a treat to target approach in inflammatory bowel disease. Expert opinion: Adalimumab is effective for the induction and maintenance of remission in patients with moderate-severe ulcerative colitis refractory to conventional therapies. At currently approved doses, it is most suitable for use in outpatients with moderate disease activity; higher doses may be required for patients with more severe disease. The convenience of self-injection will make it popular for remote patients and it may be an appropriate option in patients in whom monotherapy, rather than combination therapy with an immunomodulator, is preferred.

KW - Adalimumab

KW - anti-tumor necrosis factor alpha agents

KW - biologic therapies

KW - inflammatory bowel disease

KW - treat to target

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85016090208&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1309390

DO - 10.1080/14712598.2017.1309390

M3 - Article

VL - 17

SP - 613

EP - 621

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -